Spark Therapeutics shares slide after a setback on its hemophilia gene therapy study
Shares of Spark Therapeutics $ONCE, the most advanced gene therapy company in a growing field, were badly dented this morning after the Pfizer $PFE partner noted that one of 7 patients treated with their hemophilia B treatment experienced an immune response to the viral delivery vehicle they use.
That’s exactly what you don’t want to see in a gene therapy study, especially one this small, and Spark’s shares dropped 17% in a nasty reaction.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
